259 related articles for article (PubMed ID: 32653158)
1. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
2. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
3. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
[TBL] [Abstract][Full Text] [Related]
5. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer.
Murez T; Fléchon A; Branger N; Savoie PH; Rocher L; Camparo P; Neuville P; Ferretti L; Van Hove A; Roupret M
Prog Urol; 2022 Nov; 32(15):1066-1101. PubMed ID: 36400478
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
7. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
8. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
9. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
11. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
[TBL] [Abstract][Full Text] [Related]
12. [Intensification by high dose chemotherapy for germ-cell tumors, still an ongoing subject?].
Vinceneux A; Carbonnaux M; Fléchon A
Bull Cancer; 2020 Jun; 107(5S):S41-S48. PubMed ID: 32620206
[TBL] [Abstract][Full Text] [Related]
13. Current management of stage I testicular non-seminomatous germ cell tumours.
Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
[TBL] [Abstract][Full Text] [Related]
14. Intensive and timely chemotherapy, the key of success in testicular cancer.
Fléchon A; Culine S; Droz JP
Crit Rev Oncol Hematol; 2001 Jan; 37(1):35-46. PubMed ID: 11164717
[TBL] [Abstract][Full Text] [Related]
15. [CCAFU french national guidelines 2016-2018 on testicular germ cell tumors].
Durand X; Fléchon A; Murez T; Rocher L; Camparo P; Morel-Journel N; Savoie PH; Ferretti L; Sèbe P; Méjean A
Prog Urol; 2016 Nov; 27 Suppl 1():S147-S165. PubMed ID: 27846929
[TBL] [Abstract][Full Text] [Related]
16. How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence.
Winter C; Zengerling F; Busch J; Heinzelbecker J; Pfister D; Ruf C; Lackner J; Albers P; Kliesch S; Schmidt S; Bokemeyer C
World J Urol; 2022 Dec; 40(12):2863-2878. PubMed ID: 35554637
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacotherapy for testicular germ cell cancer.
Alsdorf W; Seidel C; Bokemeyer C; Oing C
Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience.
Faure-Conter C; Orbach D; Cropet C; Baranzelli MC; Martelli H; Thebaud E; Vérité C; Rome A; Fasola S; Corradini N; Rocourt N; Frappaz D; Kalfa N; Patte C
Pediatr Blood Cancer; 2014 Feb; 61(2):253-9. PubMed ID: 23940114
[TBL] [Abstract][Full Text] [Related]
19. Factors that impact the outcomes in testicular germ cell tumors in low-middle-income countries.
Saju SV; Radhakrishnan V; Ganesan TS; Dhanushkodi M; Raja A; Selvaluxmy G; Sagar TG
Med Oncol; 2019 Feb; 36(3):28. PubMed ID: 30725328
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer.
Kamran SC; Seisen T; Markt SC; Preston MA; Trinh QD; Frazier LA; Choueiri TK; Martin NE; Nguyen PL; Beard CJ
Eur Urol; 2018 Feb; 73(2):262-270. PubMed ID: 28687143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]